[Clinical significance of XXXX receptor expression in primary @entity157 ].

@entity1 @entity5 @entity409 @entity160 @entity157 @entity26510 @entity28575
OBJECTIVE: To investigate expression of the @entity26510 receptor ( @entity28575 ) in @entity157 ( @entity157 ) tissues and determine its clinical significance. METHODS: Cancerous and paraneoplastic liver tissues were collected from 30 @entity1 with @entity157 and from 12 @entity1 with @entity409 @entity1 (controls). Real-time PCR and immunohistochemistry were used to evaluate the expression of @entity28575 in these tissues and assess the relationship with clinical pathological features. T-test,?Fisher's exact test and Kaplan-Meier survival analysis were used for statistical analysis. RESULTS: The expression of @entity28575 in adjacent liver tissues (100%) was higher than that in the @entity157 (43.33%, P = 0.000) and normal liver tissues (41.67%, P = 0.000). The level of @entity28575 mRNA was also higher in paraneoplastic liver tissues (0.0339+/-0.0221) than in the paired @entity157 tissues (0.0127+/-0.0116, t = 2.911, P = 0.008) and normal liver tissues (0.0154+/-0.0123, t = -2.310, P = 0.033). There was no difference between the levels in @entity157 and normal liver tissues (P more than 0.05). Higher level of @entity28575 mRNA, higher level of serum @entity160 , and higher @entity5 stage (III-IV) were associated with poor prognosis (respectively 4.372, P = 0.037; 24.187, P = 0.000; 8.75, P = 0.003). However, no evident relationship between the expression of @entity28575 and other clinical features was observed. Conclusions Overexpression of @entity28575 may contribute to the occurrence and progression of @entity157 .
